(Q38386440)

English

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

scientific article published on 19 March 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

phase III clinical trial

0 references

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Veronika Bachanova

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jerzy Hołowiecki

5

object named as

Jerzy Holowiecki

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Auayporn Nademanee

2

object named as

Auayporn Nademanee

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

8

object named as

Patrick Stiff

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

John W Sweetenham

13

object named as

John Sweetenham

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

19

object named as

Naomi N Hunder

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Craig H Moskowitz

1

object named as

Craig H Moskowitz

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

object named as

Edward Agura

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

14

object named as

Anna Sureda

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

15

object named as

Dirk Huebner

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Andy I Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Alessandro M Gianni

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Angelo Carella

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Dzhelil Osmanov

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Eric L Sievers

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Andy Chi

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Emily K Larsen

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

AETHERA Study Group

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

0 references

publication date

19 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

385

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

9980

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1853-1862

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960165-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)60165-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25796459%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38386440&oldid=2081745936"